Acelyrin Inc   (SLRN)
Other Ticker:  
Price: $5.7000 $-0.13 -2.230%
Day's High: $6.1 Week Perf: 21.79 %
Day's Low: $ 5.57 30 Day Perf: 18.26 %
Volume (M): 942 52 Wk High: $ 29.88
Volume (M$): $ 5,369 52 Wk Avg: $8.71
Open: $5.85 52 Wk Low: $3.67

 Market Capitalization (Millions $) 558
 Shares Outstanding (Millions) 98
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -240
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) 2

Acelyrin Inc
Acelyrin Inc is a company that specializes in providing innovative technological solutions for various industries. They have a team of highly skilled professionals who develop cutting-edge software and hardware products to meet the unique needs of their clients.

The company focuses on delivering efficient and effective solutions that enhance business processes and improve productivity. They offer a range of services including software development, data analytics, cloud computing, cybersecurity, and artificial intelligence.

Acelyrin Inc is known for its commitment to quality and customer satisfaction. They emphasize building long-lasting relationships with their clients by understanding their requirements and delivering solutions that exceed expectations. Their strong technical expertise and industry knowledge enable them to tackle complex challenges and provide innovative solutions.

Overall, Acelyrin Inc is a technology-driven company that aims to empower businesses with advanced technological solutions to help them stay competitive and drive growth in today's digital world.

   Company Address: 4149 Liberty Canyon Road Agoura Hills 91301 CA
   Company Phone Number: 730-0360   Stock Exchange / Ticker: NASDAQ SLRN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

ACELYRIN, INC. Reports Positive Results from Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis

Published Wed, Jun 5 2024 11:00 AM UTC

ACELYRIN, INC., a renowned late-stage clinical biopharma company dedicated to advancing the development and delivery of groundbreaking medicines in immunology, has recently announced the successful outcome of its global Phase 2b/3 clinical trial of izokibep in the treatment of psoriatic arthritis (PsA). These groundbreaking results will be presented at the prestigious 2024 ...


ACELYRIN, INC. Unveils Revolutionary Drug Lonigutamab with Promising Results for Thyroi...

Published Wed, May 29 2024 11:01 AM UTC

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024Thyroid eye disease (TED), also known as Graves' ophthalmopathy, is an autoimmune condition that affects thousands of individuals worldwide. It is characterized by inflammation and swelling in the tissues around the eyes, causing eye bulging, d...

Acelyrin Inc

Acelyrin Inc Shows Significant Improvement in Financial Performance in First Quarter of 20242.

As the reporting cycle for January to March 31, 2024 resumes, several companies in the Major Pharmaceutical Preparations sector have announced their financial results. Among them is Acelyrin Inc, which published an operating shortfall of $-82.774 million for the fiscal period ending March 31, 2024. While this may initially appear concerning, a closer look at the company's progress suggests a positive outlook.
Compared to the same period last year, where the operating shortfall stood at $-179.833 million, Acelyrin Inc has made remarkable strides in improving its financial performance. This substantial reduction in operating shortfall has received affirmation from many investors, implying increased confidence in the company's potential for success.

Management Changes

Acelyrin Inc. Ramps Up Leadership Transition Amidst Financial Struggles

Published Thu, May 9 2024 12:01 PM UTC

In a recent press release, Acelyrin Inc. announced a significant leadership transition within the company. Mina Kim has been appointed as the new Chief Executive Officer and will also join the Board of Directors. This change in leadership brings a fresh perspective and a wealth of experience to guide the company through its future endeavors.
However, alongside ...

Clinical Study

Game-Changing Breakthrough in Thyroid Eye Disease Treatment: Lonigutamab Delivers Rapid Clinical Responses and Unparalleled Safety Profile

Published Wed, Mar 20 2024 11:00 AM UTC

ACELYRIN, INC. has shared groundbreaking results from their Phase 1/2 proof-of-concept study, showcasing the remarkable efficacy and safety of their innovative subcutaneous anti-IGF-1R therapy, Lonigutamab, in treating Thyroid Eye Disease (TED). This remarkable achievement marks the first time a subcutaneous anti-IGF-1R therapy has demonstrated clinical responses in patients...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com